Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Priority claimed from PCT/EP2016/059961external-prioritypatent/WO2016180695A1/en
Publication of MA42972B1publicationCriticalpatent/MA42972B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La présente invention concerne des composés de formule (i), dans laquelle r1, r2 et r3 sont tels que décrits ici, et leurs promédicaments ou un sel, un énantiomère ou un diastéréoisomère pharmaceutiquement acceptables de ceux-ci, et des compositions comprenant ces composés ainsi que des procédés d'utilisation de ces composés.The present invention relates to compounds of formula (i), wherein r1, r2 and r3 are as described herein, and their prodrugs or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions comprising these compounds. as well as methods of using these compounds.
MA42972A2015-05-082016-05-04
Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of viral infection
MA42972B1
(en)
Substituted azaindoline compounds which have an inhibitory activity of the apoptosis protein for their uses in the treatment and / or prophylaxis of cancer